Zogenix and Astellas have entered into an exclusive co-promotion agreement for Sumavel DosePro (sumatriptan injection) needle-free delivery system.
Sumavel DosePro, a needle-free delivery system for subcutaneous sumatriptan, is intended to provide migraine relief within ten minutes. Sumavel DosePro is expected to be available in January 2010.
Under the terms of the agreement, the companies will collaborate on the promotion and marketing of Sumavel DosePro. Zogenix would focus its sales activities primarily on the neurology market while Astellas will focus mostly on primary care physicians. Zogenix would be responsible for manufacturing and distribution of the product, and product sales to be booked by Zogenix.
Roger Hawley, director and CEO of Zogenix, said: “Partnering with Astellas is a significant milestone for Zogenix which will allow us to bring this cutting edge treatment to a broader number of people suffering from migraines. It was essential that we found the right partner for the introduction of our first product, Sumavel DosePro. Astellas will bring significant sales and marketing experience to our promotional efforts and help ensure the successful launch of Sumavel DosePro.”